Most Read Articles
Roshini Claire Anthony, 3 days ago

The presence of pulmonary arterial hypertension (PAH) in individuals with systemic sclerosis is associated with an increased mortality risk, a study from Singapore showed.

23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Stephen Padilla, 6 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.
19 Jan 2020
Anaemia increases mortality risk in heart failure (HF) patients across the ejection fraction (EF) spectrum, a recent study has found. The effect appears to be stronger in preserved (HFpEF) and midrange (HFmrEF) than in reduced (HFrEF) EF disease.

Diabetes mellitus negatively influences pancreatic cancer outcomes

07 Oct 2019

In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.

Researchers searched multiple online databases for studies evaluating the prognostic impact of diabetes on the clinical outcome of patients with pancreatic cancer following adjuvant chemotherapy. The regimens of chemotherapy and glucose-lowering medications used in the studies were not limited.

The meta-analysis included six case-control studies comprising 4,241 pancreatic cancer patients (median age, >55 years), among whom 1,034 had diabetes. Pancreatic cancer status was advanced or locally advanced, and gemcitabine-based regimens were frequently used for chemotherapy. Diabetes mellitus was either type 1 or type 2, with most patients treated with insulin and metformin.

Pooled data, obtained using a fixed model, revealed significant differences between diabetic pancreatic cancer patients and their nondiabetic counterparts. Specifically, diabetes exerted a negative effect on overall survival (hazard ratio, 1.16, 95 percent CI, 1.08–1.25; p=0.000) and T stage (odds ratio [OR], 1.30, 1.08–2.17; p=0.005) following chemotherapy.

On the other hand, there were no significant between-group differences in gender (OR, 1.23, 1.00–1.50; p=0.051), tumour locations (OR, 1.13, 0.81–1.56; p=0.476), cancer extent (OR, 0.85, 0.48–1.50; p=0.569), N stage (OR, 1.01, 0.58–1.74; p=0.973) and M stage (OR, 0.64, 0.21–1.99; p=0.441).

According to the researchers, further research is warranted to explore the biological mechanisms underlying the present observations, which may offer new opportunities for diagnosis and therapy in pancreatic cancer and diabetes mellitus patients.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 3 days ago

The presence of pulmonary arterial hypertension (PAH) in individuals with systemic sclerosis is associated with an increased mortality risk, a study from Singapore showed.

23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Stephen Padilla, 6 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.
19 Jan 2020
Anaemia increases mortality risk in heart failure (HF) patients across the ejection fraction (EF) spectrum, a recent study has found. The effect appears to be stronger in preserved (HFpEF) and midrange (HFmrEF) than in reduced (HFrEF) EF disease.